Skip to main content

Table 2 In-vitro kinase inhibitory activities of 7, 13–15, and sunitinib

From: Structural optimization and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential VEGFR-2/PDGFRβ inhibitors

Compound

R

IC50 (nM)

% inhibition of Aurora A at 1.0 μM

VEGFR-2

PDGFRβ

Sunitinib

–

151.8

94.5

50.7

7

–SO2N(CH2CH2Cl)2

23.7

63.2

94.4

13

–OMe

47.8

76.2

92.9

14

–OH

25.9

28.5

93.6

15

–SH

14.6

12.1

96.4

Back to article page

BMC Chemistry

ISSN: 2661-801X

Contact us